ADV300 is a novel AMES Negative HDAC6 inhibitor for the treatment of multiple cancers. Histone Deactylases (HDACs) can modulate a multitude of cellular processes and are a part of the regulation of cellular pathways involved in anti-tumor immune responses. Selective inhibition of HDAC6 slows tumor growth in various cancer models. Many prominent selective HDAC6 inhibitors are limited to pre-clinical research because they display mutagenic characteristics from the AMES test. ADV300 shows high potency against HDAC6, no mutagenicity and low cytotoxicity. Currently being evaluated in preclinical studies.